( February 11, 2026, 8:19 AM EST) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals has tentatively scheduled oral arguments for March 30 in a dispute on whether a lower court erred in granting summary judgment to the U.S. Food and Drug Administration after it was sued over the removal of tirzepatide XE "tirzepatide" , an FDA-approved drug for diabetes and weight loss, from the agency’s drug shortage list....